Ocugen (OCGN) Interest Expenses (2014 - 2026)
Ocugen's (OCGN) quarterly Interest Expenses came in at $18.1 million in Q1 2026, up 1341.53% YoY from $1.3 million in Q1 2025, and up 1260.36% on a QoQ basis from $1.3 million in Q4 2025.
Ocugen (OCGN) Interest Expenses (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Interest Expenses data on file, last reported at $18.1 million in Q1 2026.
- Quarterly Interest Expenses rose 1341.53% year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 850.18% YoY) and the FY2025 annual result came in at $136.0 million, up 13.73% from the prior year.
- Interest Expenses climbed to $18.1 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $112.4 million in Q4 2023 to a low of $29000.0 in Q3 2024.
- A 5-year average of $16.9 million and a median of $5.2 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 478520.0% — and 2024, when it tumbled 99.47%.
- Tracing OCGN's Interest Expenses over 5 years: stood at $95.7 million in 2022, then climbed by 17.43% to $112.4 million in 2023, then plunged by 99.47% to $601000.0 in 2024, then surged by 121.63% to $1.3 million in 2025, then soared by 1260.36% to $18.1 million in 2026.
- The last three Interest Expenses figures came in at $18.1 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 10.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.28 Mn |
| Jun 30, 2026 | 10.28 Mn |
| Mar 31, 2026 | 18.12 Mn |
| Mar 31, 2026 | 18.12 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 6.35 Mn |
| Jun 30, 2025 | 6.35 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 601,000.00 |
| Dec 31, 2024 | 601,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 5.54 Mn |
| Jun 30, 2024 | 5.54 Mn |
| Mar 31, 2024 | 6.19 Mn |
| Mar 31, 2024 | 6.19 Mn |